Novo Nordisk participates in USD 57m financing round at strategic partner
Beta Bionics, a partner of both Novo Nordisk and Zealand Pharma, has closed a USD 57m series C financing round with participation from existing investors, including Novo Nordisk, and one newcomer.
.jpg)
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
A partner of Danish pharmaceutical firm Novo Nordisk, US-based Beta Bionics, has been on a successful capital hunt, bringing in USD 57m in a series C financing round, the company informs in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma enters US partnership over pump system
For subscribers
Novo Nordisk sues Teva over generic drug development
For subscribers
.jpg&w=384&q=75)
